LongBio Pharma (Suzhou) Co., Ltd. (Ticker: 1779 HK) is a Chinese clinical-stage biopharmaceutical company focused on in-house discovery and development of biologic treatments for allergic and autoimmune diseases. Its pipeline includes LP-003, an anti-IgE antibody targeting allergic rhinitis, chronic spontaneous urticaria, allergic asthma and other allergic diseases, and LP-005, a bi-functional antibody fusion protein targeting C5 and C3b complement for renal and hematologic indications. The company is domiciled in China.

LongBio Pharma plans to list H shares on the Hong Kong Stock Exchange on June 5, 2026. According to published terms, the company is offering 14.19 million primary H shares at HKD 96.06 per share, raising approximately HKD 1.36 billion, or about $174 million. The market capitalization at offer is indicated at approximately HKD 7.01 billion, equivalent to around $894 million.

According to the prospectus, IPO proceeds are expected to be used for R&D and product capacity, as well as working capital and strategic acquisitions. The offering consists entirely of primary shares and includes a 15% greenshoe option.